Threshold Halts Development Of Glufosfamide In Lung Cancer
This article was originally published in The Pink Sheet Daily
Announcement comes after drug failed to produce more than one confirmed partial response in first stage of a Phase II trial.
You may also be interested in...
Threshold Pharmaceuticals’ lead compound from its hypoxia-activated prodrug platform, TH-302, is partnered with Merck KGaA on one Phase III program and in internal development for another Phase III.
Company is exploring next steps for the oncologic in the pancreatic cancer setting while trials are ongoing for other cancers.
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.